Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark Hamilton, Ajlan Al Zaki, Lei Feng, Zachary Hunzeker, Dai Chihara, Hun Lee, Chitra Hosing, Laura Ebarle, Oluwadare Ajishegiri, Jason Westin, Sairah Ahmed, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2025-5485

Published: 2025

Journal Articles

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Blood (2025) 146 (Supplement 1): 566.

https://doi.org/10.1182/blood-2025-566

Published: 2025

Journal Articles

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Blood (2025) 146 (Supplement 1): 5330.

https://doi.org/10.1182/blood-2025-5330

Published: 2025

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion

Chaitanya Acharya, Reyka Jayasinghe, Darwin D'Souza, Mark Hamilton, Steven Foltz, Zhihong Chen, Seunghee Kim-Schulze, Hearn Cho, Shaji Kumar, George Mulligan

Blood (2025) 146 (Supplement 1): 3955.

https://doi.org/10.1182/blood-2025-3955

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: A real world pharmacovigilance analysis

Medha Belwadi, Mark Hamilton, Yinghong Wang, Sairah Ahmed, David Richards, Rahul Banerjee, Nilesh Kalariya, Baldeep Pabla, Neeraj Saini, Oren Pasvolsky, J Christine Ye, Mahmoud Gaballa, Sa Wang, L. Jeffrey Medeiros, Francisco Vega, Krina Patel, Swami Iyer

Blood (2025) 146 (Supplement 1): 6366.

https://doi.org/10.1182/blood-2025-6366

Published: 2025

Journal Articles

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2025-3691

Published: 2025

Journal Articles

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Blood (2025) 146 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2025-4159

Published: 2025

Journal Articles

Immunomodulatory Effects of MEK Inhibition in Multiple Myeloma

Chaitanya Acharya, Reyka G. Jayasinghe, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn Jay Cho, Shaji Kumar, George Mulligan

Blood (2024) 144 (Supplement 1): 6863.

https://doi.org/10.1182/blood-2024-210989

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Robert M Chavez, Doris R. Powell, Kiran Lakhani, John Attelah, Erin Flynt, Terry Connolly, Mark Hamilton, George Mulligan, Daniel Auclair, Jonathan Keats, Paula M Vertino, Lawrence H. Boise, Sagar Lonial, Karen N Conneely, Benjamin G. Barwick

Blood (2024) 144 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2024-210929

Published: 2024

Journal Articles

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Junia Vieira, Alison S Park, Edgar Gonzalez-Kozlova, David Melnekoff, Sherry Bhalla, Chaitanya Acharya, Mark Hamilton, George Mulligan, Immune Atlas Network, Hearn Jay Cho, Li Ding, Sacha Gnjatic, Ioannis S Vlachos, Manoj Bhasin, Sundar Jagannath, Samir Parekh, Alessandro Lagana

Blood (2024) 144 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2024-208677

Published: 2024

Journal Articles

Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment

Blood (2024) 144 (Supplement 1): 3258.

https://doi.org/10.1182/blood-2024-211579

Published: 2024

Journal Articles

DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease

Benjamin G. Barwick, Robert M Chavez, Doris R. Powell, Yu Zhang, Mark Hamilton, Daniel Auclair, George Mulligan, Karen N Conneely, Jonathan J Keats, Paula M Vertino, Lawrence H. Boise, Sagar Lonial

Blood (2024) 144 (Supplement 1): 251.

https://doi.org/10.1182/blood-2024-201447

Published: 2024

Journal Articles

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 96.

https://doi.org/10.1182/blood-2024-205378

Published: 2024

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects

Blood (2023) 142 (Supplement 1): 2548.

https://doi.org/10.1182/blood-2023-178062

Published: 2023

Journal Articles

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Blood (2022) 140 (Supplement 1): 7158–7159.

https://doi.org/10.1182/blood-2022-167212

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: A real world pharmacovigilance analysis

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Immunomodulatory Effects of MEK Inhibition in Multiple Myeloma

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment

DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only